Eric Lefkofsky has not taken a single science class since he was in college. With that being said, as he meanders through his medical startup, the Chicago lab of Tempus, he presents the air of an expert. Pointing to a pathology slide of a patients who was diagnosed with breast cancer he states “one thing that you see right from the start is a purple like stain in this cell”. Eric also talks about how tempus is trying to bring the unknown power of artificial intelligence to the world of health care.
This 49 year old has launched up to 5 different companies that are worth a minimum of $250 million each. Each one of his companies promise to transform its industry by using really big data. The company that he is best known for is Groupon. Putting the deals site’s share price disappointment aside, Lefkofsky is estimated to be worth $2.7 billion. His company Tempus is a simply something that was predicated on the simply theory that lots of information will give doctors the ability to personalize all cancer treatments and thus make them more effective. For example, if a doctor is treating a patient with lung cancer, they would send a tumor sample to Tempus. Then Tempus would identify a mutation in the gene for the growth receptor, which would cause the cells to start to grow and divide way to much. With this, the doctor could then prescribe a targeted therapy for the patient and they would have better result than chemotherapy.
So far the company has around 700 employees and has raised $520 million. The $3.1 billion valuation suggest that the investors expect this approach to be a huge scorer. Starting with cancers, then moving on to treating more chronic conditions like diabetes and or depression.